Tiziana (TILS), also listed on NASDAQ (Symbol TLSA), is driving forwards the clinical development plan for its fully-human mAb TZLS-501 for treating COVID-19 respiratory symptoms and has set out the detail of its clinical plan being executed by a group of specialist contract research organisations
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Tiziana Life Sciences: Advancing at speed
- Published:
05 Aug 2020 -
Author:
Emma Ulker -
Pages:
4
Tiziana (TILS), also listed on NASDAQ (Symbol TLSA), is driving forwards the clinical development plan for its fully-human mAb TZLS-501 for treating COVID-19 respiratory symptoms and has set out the detail of its clinical plan being executed by a group of specialist contract research organisations